Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | AXL | P30530 | 1/20 | 0.35 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.35 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3544906 | 0.81 | GPR35 (0.39) | ALDH1A1MAPTPDPK1PARP1HPGD | |
| SCHEMBL30488581 | 0.81 | AXL (0.42) | ALDH1A1MAPTPDPK1PARP1AXL | |
| SCHEMBL17305955 | 0.81 | PDPK1 (0.40) | PDPK1PARP1AXLMKNK1MKNK2 | |
| SCHEMBL3548733 | 0.81 | AXL (0.42) | ALDH1A1MAPTPDPK1PARP1AXL | |
| SCHEMBL30598786 | 0.77 | POLB (0.37) | ALDH1A1MAPTPDPK1PARP1HPGD | |
| SCHEMBL3543082 | 0.77 | POLB (0.37) | ALDH1A1MAPTPDPK1PARP1HPGD | |
| SCHEMBL9838214 | 0.74 | DYRK1A (0.42) | ALDH1A1MAPTPDE7ACDK2HPGD | |
| SCHEMBL28471596 | 0.74 | PDE4A (0.40) | ALDH1A1MAPTPDE7APDE4APDE4B | |
| SCHEMBL31025953 | 0.73 | AXL (0.42) | ALDH1A1MAPTPDPK1PARP1HPGD | |
| SCHEMBL10768234 | 0.73 | AXL (0.42) | ALDH1A1MAPTPDPK1PARP1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055119-A9 | TRICYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF | SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD (CN) | 2026-02-26 | — | — | US | disclosed |
| US-20250257071-A9 | TRICYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2025-08-14 | — | — | US | disclosed |
| US-20250195683-A1 | ANTIBODY-DRUG CONJUGATE, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEROF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2025-06-19 | — | — | US | disclosed |
| EP-4516321-A1 | ANTIBODY-DRUG CONJUGATE, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2025-03-05 | — | — | EP | disclosed |
| US-20250002502-A1 | TRICYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF | SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD (CN) | 2025-01-02 | — | — | US | disclosed |
| EP-4458830-A1 | TRICYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2024-11-06 | — | — | EP | disclosed |
| CN-118829451-A | Antibody drug conjugate, pharmaceutical composition and application thereof | 四川科伦博泰生物医药股份有限公司 | 2024-10-22 | — | — | CN | disclosed |
| WO-2023207710-A9 | ANTIBODY-DRUG CONJUGATE, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2024-07-25 | — | — | WO | disclosed |
| US-20240228508-A1 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION | 2024-07-11 | — | — | US | disclosed |
| CN-118201933-A | Tri-fused ring compounds, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2024-06-14 | — | — | CN | disclosed |
| WO-2023207710-A1 | ANTIBODY-DRUG CONJUGATE, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2023-11-02 | — | — | WO | disclosed |
| WO-2023125121-A1 | TRICYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2023-07-06 | — | — | WO | disclosed |
| EP-0223420-B1 | CONDENSED IMIDAZOPYRIDINE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 1991-02-27 | — | — | EP | disclosed |
| US-4753951-A | ANTIDEPRESSANTS, ANXIOLYTICS | SHIONOGI & CO., LTD. (JP) | 1988-06-28 | — | — | US | disclosed |
| EP-0223420-A1 | Condensed imidazopyridine derivatives | SHIONOGI & CO., LTD. (JP) | 1987-05-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228508-A1 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | ALDH1A1 4431/4885MAPT 3080/4885PDPK1 352/4885 |
| US-20250195683-A1 | ANTIBODY-DRUG CONJUGATE, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEROF | CD47, ABCB1, EGFR | ALDH1A1 755/4885MAPT 285/4885PDPK1 4230/4885 |
| US-20250257071-A9 | TRICYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF | CYP11B2, CYP11B1, CYP3A5 | ALDH1A1 1601/4885MAPT 49/4885PDPK1 3549/4885 |
| US-20260055119-A9 | TRICYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF | CYP11B1, CYP11B2, CYP2D6 | ALDH1A1 1379/4885MAPT 616/4885PDPK1 4453/4885 |
| US-20250002502-A1 | TRICYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF | CYP11B2, CYP11B1, CYP3A5 | ALDH1A1 1601/4885MAPT 49/4885PDPK1 3549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.